Biweekly SOLAR, as First-line C/T in Pts With Gastric, Pancreatic and Biliary Cancers
Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The primary purpose of the study is to determine the maximal tolerated dose (MTD) of
Oxaliplatin in this phase I study. The secondary objectives are to determine the response
rate, progression free survival, overall survival, and safety profiles.
Eligible patients will receive a triplet chemotherapy consisting of nab-paclitaxel
(Abraxane®) 150 mg/m2 IVD 30 min followed by Oxaliplatin 60 - 85 mg/m2 IVD 2hr at D1, plus
oral S-1 35mg/m2 and Leucovorin 30mg twice daily from D1 to D7, every 14 days as a cycle till
disease progression.
Phase:
Phase 1
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
National Cheng-Kung University Hospital National Taiwan University Hospital